首页> 美国卫生研究院文献>BMC Cancer >High Beclin-1 and ARID1A expression corelates with poor survival and high recurrence in intrahepatic cholangiocarcinoma: a histopathological retrospective study
【2h】

High Beclin-1 and ARID1A expression corelates with poor survival and high recurrence in intrahepatic cholangiocarcinoma: a histopathological retrospective study

机译:Beclin-1和ARID1A的高表达与肝内胆管癌的不良生存率和高复发率相关:一项组织病理学回顾性研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundAlthough surgical resection provides a cure for patients with intrahepatic cholangiocarcinoma (ICC), the risk of mortality and recurrence remains high. Several biomarkers are reported to be associated with the prognosis of ICC, including Beclin-1, ARID1A, carbonic anhydrase IX (CA9) and isocitrate dehydrogenase 1 (IDH1), but results are inconsistent. Therefore, a histopathological retrospective study was performed to simultaneously investigate the relationship of these four potential biomarkers with clinicopathological parameters and their prognostic values in patients with ICC.
机译:背景尽管外科手术切除可以治愈肝内胆管癌(ICC)患者,但死亡和复发的风险仍然很高。据报道有几种生物标志物与ICC的预后有关,包括Beclin-1,ARID1A,碳酸酐酶IX(CA9)和异柠檬酸脱氢酶1(IDH1),但结果不一致。因此,进行了组织病理学回顾性研究,以同时调查这四种潜在生物标志物与ICC患者临床病理参数的关系及其预后价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号